Johnson & Johnson (JNJ)
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government
In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest designation of AAA to AA+, citing budgetary issues. Fitch once again downgraded U.S. credit in 2023 and Moody's recently suggested it's contemplating a similar move.
Johnson & Johnson Pivots Its AI Strategy
The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
The Relief Rally Is Over: 4 Incredible Dividend Monarchs Are Our Safest Ideas Now
While it was fun while it lasted, as we have discussed before, inevitably, after vicious sell-offs like the one we saw from the market peak in February, which pushed the S&P 500 and the Nasdaq quickly into a brief bear market 20% decline territory, there is the potential for stunning bear market rallies.
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
On the one hand, the company beat on the top and bottom lines and offered better-than-expected guidance. On the other hand, JNJ acknowledged the likelihood of a $400 million tariff hit on the company's medical device business that will impact business in the short term.
J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts say
Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter-over-quarter Spravato sales growth supporting the notion psychedelics can become commercially viable in mental health.
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer John Reed - EVP, Innovative Medicine, R&D Joseph Wolk - EVP, Chief Financial Officer Jennifer Taubert - EVP, Worldwide Chairman, Innovative Medicine Tim Schmid - EVP, Worldwide Chairman, MedTech Conference Call Participants Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Asad Haider - Goldman Sachs Danielle Antalffy - UBS Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Matt Miksic - Barclays Tim Anderson - Bank of America Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and increased its dividend, reflecting confidence in long-term growth despite short-term litigation and tariff uncertainties.
